{"ticker": {"uuid": "ae2fcad0-4fa0-4de0-b97c-53f19ad62eb3", "symbol": "VECT", "name": "VectivBio Holding AG", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Pharmaceuticals"}, "articles": [{"title": "Q1 Earnings Review: Branded Pharmaceuticals Stocks Led by Eli Lilly (NYSE:LLY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQVTFBdTdVbEotRDE1Z3Y1bWU3Y0o3aGlnZWowOWUzMzdaYmdjMGhRTHYwMUxUbFFydnl6VGVLQlVlZE1QSzVTckpzWUs4QmhxeXk0T0FvUjJPclFzZS1jcmNsdEJaM0hCcll3YllCdFpqZUxRNTB1SENPWmgtanRmenA2c1liUHdPYUkzdW9PSTZZOWNlSnViYjd3OVQyWU9jUU1jaUFQWmo2UVY0bGJFRw?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQTnRnX1FWOEVnbUtrTDJxRV9yZEVIVWowQ1ZDbENGUnByN1M1SVdRd0VtRnJmVnBtaWxIN2lneGc1NHRBY2FOZjR5dE5HTnZ6ek1tMFF2ZmU4X3FjNVh6SXlVQ2pzOEFVQ3BtZ0dUY1FlZXRrY3JXVWN5b0xuR3RCcjRmdFNaRzZXbS0yOEVJc2RLekoyVk9YTDFLc05OUnBxaG1RbWZXRHhrRUM4dzdibHZmU0w?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObmtkMExEMGwzLWo3NllPMlhodHBXYVlYRU1aRXhmd2FNTWo1dXI3SmVzZzNJVWJ1VEhXSExZYU00aHVmenZ2bmpOa0lDMmhTa083ZWRvbGlNZ2xobWtwdkxlX292cGU5Rzh5NV9odUhLdGZsRl81RVVGNmcta2VWek5VNzM5a2xsYlQxTk14RnJKcVRFY1JYQXRaLXZaUmM?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "VECT - Vectivbio Holding Ag Latest Stock News & Market Updates", "summary": "This page provides investors with the latest news and market updates for Vectivbio Holding (Ticker: VECT). It features high-quality news articles, expert summaries from Rhea-AI detailing their impact and sentiment, and end-of-day stock performance summaries. The content covers va", "url": "https://www.stocktitan.net/news/VECT/", "source_name": "Stock Titan", "published_at": "2026-03-31T05:09:16", "published_display": "31 Mar 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectivBio with strong debut on Nasdaq", "summary": "VectivBio, a clinical-stage biopharmaceutical company focused on rare conditions, made a strong debut on the Nasdaq Global Select Market, with its shares closing up 42.5% on the first trading day. The Basel-based company secured approximately $146.6 million from its initial publi", "url": "https://www.startupticker.ch/en/news/vectivbio-with-strong-debut-on-nasdaq", "source_name": "Startupticker.", "published_at": "2026-01-19T12:57:16", "published_display": "19 Jan 2026 12:57", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech acquired by Ironwood faces allegations of misappropriating trade secrets", "summary": "Ironwood Pharmaceuticals is reportedly in settlement discussions with Ferring regarding trade secret claims connected to apraglutide, a key asset in Ironwood's $1 billion acquisition of VectivBio. The lawsuit alleges misappropriation of trade secrets, bringing the company's signi", "url": "https://www.bizjournals.com/boston/news/2025/11/11/ironwood-vectivbio-lawsuit.html", "source_name": "The Business Journals", "published_at": "2025-11-11T18:39:06", "published_display": "11 Nov 2025 18:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD) for $17.00 per share in cash. The firm is examining whether this consideration and the sale process adequately value VectivB", "url": "https://markets.financialcontent.com/wral/article/bizwire-2023-5-25-vectivbio-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-vectivbio-holding-ag-vect", "source_name": "FinancialContent", "published_at": "2025-10-21T08:02:43", "published_display": "21 Oct 2025 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares", "summary": "Ironwood Pharmaceuticals, Inc. successfully completed its tender offer to acquire VectivBio Holding AG shares for $17.00 per share, with approximately 97.60% of outstanding shares tendered. Following the acquisition, VectivBio's directors have been replaced by Ironwood-appointed ", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2023-6-29-ironwood-and-vectivbio-announce-the-completion-of-the-tender-offer-for-vectivbio-shares?CSSURL=36.htm", "source_name": "FinancialContent", "published_at": "2025-10-21T08:02:43", "published_display": "21 Oct 2025 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDGAR Filing Documents for 0001628280-21-017820", "summary": "This document is an EDGAR filing detail for Form 6-K (Report of foreign issuer) by VectivBio Holding AG. The filing, with accession number 0001628280-21-017820, was accepted on August 31, 2021, and includes various documents and graphics related to the company. It provides inform", "url": "https://www.sec.gov/Archives/edgar/data/1836379/0001628280-21-017820-index.htm", "source_name": "SEC.gov", "published_at": "2024-03-11T00:09:09", "published_display": "11 Mar 2024 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penticton Herald: Finance - Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio", "summary": "Ironwood Pharmaceuticals, Inc. announced the successful completion of a squeeze-out merger with VectivBio Holding AG, where VectivBio merged into Ironwood Pharmaceuticals GmbH. This merger resulted in the cancellation of all remaining outstanding VectivBio shares, converting them", "url": "https://markets.financialcontent.com/pentictonherald/article/bizwire-2023-12-12-ironwood-announces-the-completion-of-squeeze-out-merger-with-vectivbio", "source_name": "FinancialContent", "published_at": "2023-12-12T16:01:00", "published_display": "12 Dec 2023 16:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WaterWorld - Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio", "summary": "Ironwood Pharmaceuticals, Inc. announced the successful completion of a squeeze-out merger under Swiss law with VectivBio Holding AG. As a result, all remaining outstanding shares of VectivBio not previously purchased by Ironwood have been cancelled and converted into the right t", "url": "https://markets.financialcontent.com/pennwell.waterworld/article/bizwire-2023-12-12-ironwood-announces-the-completion-of-squeeze-out-merger-with-vectivbio", "source_name": "FinancialContent", "published_at": "2023-12-12T16:01:00", "published_display": "12 Dec 2023 16:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penticton Herald: Finance - Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares", "summary": "Ironwood Pharmaceuticals and VectivBio announced the successful completion of the tender offer for VectivBio's outstanding ordinary shares at $17.00 per share. Approximately 97.60% of shares were tendered, and Ironwood has accepted these shares for payment. Ironwood plans to deli", "url": "https://markets.financialcontent.com/pentictonherald/article/bizwire-2023-6-29-ironwood-and-vectivbio-announce-the-completion-of-the-tender-offer-for-vectivbio-shares", "source_name": "FinancialContent", "published_at": "2023-06-29T08:30:00", "published_display": "29 Jun 2023 08:30", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio", "summary": "Ironwood Pharmaceuticals and VectivBio Holding AG announced that the Hart-Scott-Rodino waiting period for Ironwood's proposed acquisition of VectivBio has expired. This expiration fulfills one of the conditions for the tender offer, which involves Ironwood purchasing VectivBio's ", "url": "https://www.businesswire.com/news/home/20230616065227/en/Ironwood-and-VectivBio-Announce-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Proposed-Acquisition-of-VectivBio", "source_name": "Business Wire", "published_at": "2023-06-16T11:08:53", "published_display": "16 Jun 2023 11:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD) for $17.00 per share in cash. KSF seeks to determine if this consideration and the process leading to it are adequate, or if", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2023-6-6-vectivbio-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-vectivbio-holding-ag-vect?Language=english", "source_name": "FinancialContent", "published_at": "2023-06-06T11:58:00", "published_display": "06 Jun 2023 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HMPT, VECT, PDCE, GHL", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties concerning the sales of Home Point Capital Inc., VectivBio Holding AG, PDC Energy, Inc., and Greenhill & Co., Inc. The firm encourages ", "url": "https://www.globenewswire.com/news-release/2023/06/04/2681552/0/en/shareholder-investigation-halper-sadeh-llc-investigates-hmpt-vect-pdce-ghl.html", "source_name": "GlobeNewswire", "published_at": "2023-06-04T23:14:46", "published_display": "04 Jun 2023 23:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sizing up VectivBio\u2019s takeout premium among '23 M&A deals", "summary": "This article analyzes the premium paid for VectivBio in its acquisition by Ironwood, comparing it to other biopharma M&A deals valued over $1 billion in 2023. While VectivBio's deal premium appeared modest, a preceding stock run-up influenced the final percentage. The article not", "url": "https://www.biocentury.com/article/648021/sizing-up-vectivbio-s-takeout-premium-among-23-m-a-deals", "source_name": "BioCentury", "published_at": "2023-05-24T16:11:25", "published_display": "24 May 2023 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham & Watkins Advises Ironwood Pharmaceuticals in Acquisition of VectivBio", "summary": "Latham & Watkins represented Ironwood Pharmaceuticals in its US$1 billion acquisition of VectivBio Holding AG. The multidisciplinary deal team included corporate, finance, tax, IP, data privacy, benefits, FDA, healthcare regulatory, and antitrust specialists across multiple offic", "url": "https://www.lw.com/en/news/latham-watkins-advises-ironwood-pharmaceuticals-in-acquisition-of-vectivbio", "source_name": "Latham & Watkins LLP", "published_at": "2023-05-22T13:39:12", "published_display": "22 May 2023 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "May 22 Quick Takes: Ironwood building GI franchise via $1B VectivBio acquisition", "summary": "Ironwood Pharmaceuticals Inc. announced its acquisition of VectivBio Holding AG for $1 billion, integrating GLP2 analog apraglutide into its gastrointestinal portfolio. VectivBio, a 2019 spinout, had advanced apraglutide into Phase III testing for short bowel syndrome. Additional", "url": "https://www.biocentury.com/article/648025/may-22-quick-takes-ironwood-building-gi-franchise-via-1b-vectivbio-acquisition", "source_name": "BioCentury", "published_at": "2023-05-22T10:44:00", "published_display": "22 May 2023 10:44", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood to buy Swiss biotech for $1 billion", "summary": "Ironwood Pharmaceuticals announced its plan to acquire Swiss biotech firm VectivBio Holding AG for $1 billion. This all-cash offer strengthens Ironwood's focus on gastrointestinal treatments and will add apraglutide, an experimental drug for short bowel syndrome, to its pipeline.", "url": "https://www.bostonglobe.com/2023/05/22/business/ironwood-buy-swiss-biotech-1-billion/", "source_name": "The Boston Globe", "published_at": "2023-05-22T05:01:32", "published_display": "22 May 2023 05:01", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood To Acquire VectivBio For $1 Billion", "summary": "Ironwood Pharmaceuticals, Inc. announced its definitive agreement to acquire VectivBio Holding AG for approximately $1 billion in an all-cash transaction. The acquisition price of $17.00 per share represents an 80% premium over VectivBio's volume-weighted average share price. Thi", "url": "https://www.citybiz.co/article/419580/ironwood-pharmaceuticals-to-acquire-vectivbio/", "source_name": "citybiz", "published_at": "2023-05-22T05:01:32", "published_display": "22 May 2023 05:01", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood to buy VectivBio for $1.15 bln to boost digestive disorder drugs portfolio", "summary": "Ironwood Pharmaceuticals Inc is set to acquire VectivBio Holding AG for $1.15 billion, paying $17 per share. This strategic move aims to enhance Ironwood's portfolio of experimental digestive disorder drugs, particularly with VectivBio's apraglutide, which is projected to achieve", "url": "https://health.economictimes.indiatimes.com/news/mergers-and-aquisitions/ironwood-to-buy-vectivbio-for-1-15-bln-to-boost-digestive-disorder-drugs-portfolio/100425105", "source_name": "ET HealthWorld", "published_at": "2023-05-22T02:35:00", "published_display": "22 May 2023 02:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "About Us | Oil & Gas Journal - VectivBio Publishes Invitation to the Annual General Meeting", "summary": "VectivBio Holding AG published the invitation to its 2023 Annual General Meeting, scheduled for June 1, 2023, in Basel, Switzerland. Shareholders registered by May 2, 2023, are eligible to participate and can find further details on how to attend or vote online. VectivBio is a cl", "url": "https://markets.financialcontent.com/pennwell.oilgasjournal/article/gnwcq-2023-5-10-vectivbio-publishes-invitation-to-the-annual-general-meeting", "source_name": "FinancialContent", "published_at": "2023-05-10T08:59:00", "published_display": "10 May 2023 08:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectivBio Holding (NASDAQ:VECT) shareholder returns have been strong, earning 113% in 1 year", "summary": "VectivBio Holding AG (NASDAQ:VECT) has seen a significant increase in shareholder returns, with shares soaring 113% over the past year and 42% in the last quarter, possibly attributed to recent financial results. The company, which is not yet profitable, shows strong revenue grow", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vect/vectivbio-holding/news/vectivbio-holding-nasdaqvect-shareholder-returns-have-been-s/amp", "source_name": "Simply Wall Street", "published_at": "2023-04-22T07:29:47", "published_display": "22 Apr 2023 07:29", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Watkins Advises on VectivBio\u2019s US$125 Million Underwritten Offering of Ordinary Shares", "summary": "Latham & Watkins LLP advised the underwriters in VectivBio Holding AG's US$125 million underwritten offering of 16,700,000 ordinary shares at US$7.50 per share. The offering, which attracted investments from several specialist biotech investors, is expected to close on or about O", "url": "https://www.lw.com/en/news/2022/10/latham-advises-vectivbio-underwritten-offering-ordinary-shares", "source_name": "Latham & Watkins LLP", "published_at": "2022-10-13T19:06:30", "published_display": "13 Oct 2022 19:06", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares", "summary": "VectivBio Holding AG announced the pricing of an underwritten offering of 16,700,000 ordinary shares at $7.50 per share, aiming to raise approximately $125 million. The proceeds will fund clinical development and pre-commercialization activities for its lead product candidate, ap", "url": "https://www.globenewswire.com/news-release/2022/10/13/2533721/0/en/VectivBio-Announces-Pricing-of-125-Million-Underwritten-Offering-of-Ordinary-Shares.html", "source_name": "GlobeNewswire", "published_at": "2022-10-13T10:51:35", "published_display": "13 Oct 2022 10:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WaterWorld - VectivBio Announces Date of Extraordinary General Meeting of Shareholders", "summary": "VectivBio Holding AG announced that its Extraordinary General Meeting of Shareholders will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT. The sole agenda item is the election of Wouter Joustra to the Board of Directors. Due to the COVID-19 pandemic, the ", "url": "https://markets.financialcontent.com/pennwell.waterworld/article/gnwcq-2022-10-12-vectivbio-announces-date-of-extraordinary-general-meeting-of-shareholders", "source_name": "FinancialContent", "published_at": "2022-10-12T10:00:00", "published_display": "12 Oct 2022 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectivBio Says Combined Proceeds From Public Offering And Private Sale Total $50 Mln", "summary": "VectivBio Holding AG announced a follow-on public offering of 5.72 million ordinary shares at $5.25 per share, yielding approximately $30 million. Concurrently, it entered a private placement agreement with Forbion Growth Opportunities Fund II to sell 3.48 million ordinary shares", "url": "https://www.rttnews.com/3290581/vectivbio-says-combined-proceeds-from-public-offering-and-private-sale-total-50-mln.aspx", "source_name": "RTTNews", "published_at": "2022-06-14T23:06:00", "published_display": "14 Jun 2022 23:06", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "VECT - Vectivbio Holding Ag Latest Stock News & Market Updates", "summary": "This page provides investors with the latest news and market updates for Vectivbio Holding (Ticker: VECT). It features high-quality news articles, expert summaries from Rhea-AI detailing their impact and sentiment, and end-of-day stock performance summaries. The content covers va", "url": "https://www.stocktitan.net/news/VECT/", "source_name": "Stock Titan", "published_at": "2026-03-31T05:09:16", "published_display": "31 Mar 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectivBio with strong debut on Nasdaq", "summary": "VectivBio, a clinical-stage biopharmaceutical company focused on rare conditions, made a strong debut on the Nasdaq Global Select Market, with its shares closing up 42.5% on the first trading day. The Basel-based company secured approximately $146.6 million from its initial publi", "url": "https://www.startupticker.ch/en/news/vectivbio-with-strong-debut-on-nasdaq", "source_name": "Startupticker.", "published_at": "2026-01-19T12:57:16", "published_display": "19 Jan 2026 12:57", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech acquired by Ironwood faces allegations of misappropriating trade secrets", "summary": "Ironwood Pharmaceuticals is reportedly in settlement discussions with Ferring regarding trade secret claims connected to apraglutide, a key asset in Ironwood's $1 billion acquisition of VectivBio. The lawsuit alleges misappropriation of trade secrets, bringing the company's signi", "url": "https://www.bizjournals.com/boston/news/2025/11/11/ironwood-vectivbio-lawsuit.html", "source_name": "The Business Journals", "published_at": "2025-11-11T18:39:06", "published_display": "11 Nov 2025 18:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD) for $17.00 per share in cash. The firm is examining whether this consideration and the sale process adequately value VectivB", "url": "https://markets.financialcontent.com/wral/article/bizwire-2023-5-25-vectivbio-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-vectivbio-holding-ag-vect", "source_name": "FinancialContent", "published_at": "2025-10-21T08:02:43", "published_display": "21 Oct 2025 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares", "summary": "Ironwood Pharmaceuticals, Inc. successfully completed its tender offer to acquire VectivBio Holding AG shares for $17.00 per share, with approximately 97.60% of outstanding shares tendered. Following the acquisition, VectivBio's directors have been replaced by Ironwood-appointed ", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2023-6-29-ironwood-and-vectivbio-announce-the-completion-of-the-tender-offer-for-vectivbio-shares?CSSURL=36.htm", "source_name": "FinancialContent", "published_at": "2025-10-21T08:02:43", "published_display": "21 Oct 2025 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDGAR Filing Documents for 0001628280-21-017820", "summary": "This document is an EDGAR filing detail for Form 6-K (Report of foreign issuer) by VectivBio Holding AG. The filing, with accession number 0001628280-21-017820, was accepted on August 31, 2021, and includes various documents and graphics related to the company. It provides inform", "url": "https://www.sec.gov/Archives/edgar/data/1836379/0001628280-21-017820-index.htm", "source_name": "SEC.gov", "published_at": "2024-03-11T00:09:09", "published_display": "11 Mar 2024 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penticton Herald: Finance - Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio", "summary": "Ironwood Pharmaceuticals, Inc. announced the successful completion of a squeeze-out merger with VectivBio Holding AG, where VectivBio merged into Ironwood Pharmaceuticals GmbH. This merger resulted in the cancellation of all remaining outstanding VectivBio shares, converting them", "url": "https://markets.financialcontent.com/pentictonherald/article/bizwire-2023-12-12-ironwood-announces-the-completion-of-squeeze-out-merger-with-vectivbio", "source_name": "FinancialContent", "published_at": "2023-12-12T16:01:00", "published_display": "12 Dec 2023 16:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WaterWorld - Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio", "summary": "Ironwood Pharmaceuticals, Inc. announced the successful completion of a squeeze-out merger under Swiss law with VectivBio Holding AG. As a result, all remaining outstanding shares of VectivBio not previously purchased by Ironwood have been cancelled and converted into the right t", "url": "https://markets.financialcontent.com/pennwell.waterworld/article/bizwire-2023-12-12-ironwood-announces-the-completion-of-squeeze-out-merger-with-vectivbio", "source_name": "FinancialContent", "published_at": "2023-12-12T16:01:00", "published_display": "12 Dec 2023 16:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penticton Herald: Finance - Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares", "summary": "Ironwood Pharmaceuticals and VectivBio announced the successful completion of the tender offer for VectivBio's outstanding ordinary shares at $17.00 per share. Approximately 97.60% of shares were tendered, and Ironwood has accepted these shares for payment. Ironwood plans to deli", "url": "https://markets.financialcontent.com/pentictonherald/article/bizwire-2023-6-29-ironwood-and-vectivbio-announce-the-completion-of-the-tender-offer-for-vectivbio-shares", "source_name": "FinancialContent", "published_at": "2023-06-29T08:30:00", "published_display": "29 Jun 2023 08:30", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio", "summary": "Ironwood Pharmaceuticals and VectivBio Holding AG announced that the Hart-Scott-Rodino waiting period for Ironwood's proposed acquisition of VectivBio has expired. This expiration fulfills one of the conditions for the tender offer, which involves Ironwood purchasing VectivBio's ", "url": "https://www.businesswire.com/news/home/20230616065227/en/Ironwood-and-VectivBio-Announce-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Proposed-Acquisition-of-VectivBio", "source_name": "Business Wire", "published_at": "2023-06-16T11:08:53", "published_display": "16 Jun 2023 11:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD) for $17.00 per share in cash. KSF seeks to determine if this consideration and the process leading to it are adequate, or if", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2023-6-6-vectivbio-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-vectivbio-holding-ag-vect?Language=english", "source_name": "FinancialContent", "published_at": "2023-06-06T11:58:00", "published_display": "06 Jun 2023 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HMPT, VECT, PDCE, GHL", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties concerning the sales of Home Point Capital Inc., VectivBio Holding AG, PDC Energy, Inc., and Greenhill & Co., Inc. The firm encourages ", "url": "https://www.globenewswire.com/news-release/2023/06/04/2681552/0/en/shareholder-investigation-halper-sadeh-llc-investigates-hmpt-vect-pdce-ghl.html", "source_name": "GlobeNewswire", "published_at": "2023-06-04T23:14:46", "published_display": "04 Jun 2023 23:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sizing up VectivBio\u2019s takeout premium among '23 M&A deals", "summary": "This article analyzes the premium paid for VectivBio in its acquisition by Ironwood, comparing it to other biopharma M&A deals valued over $1 billion in 2023. While VectivBio's deal premium appeared modest, a preceding stock run-up influenced the final percentage. The article not", "url": "https://www.biocentury.com/article/648021/sizing-up-vectivbio-s-takeout-premium-among-23-m-a-deals", "source_name": "BioCentury", "published_at": "2023-05-24T16:11:25", "published_display": "24 May 2023 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham & Watkins Advises Ironwood Pharmaceuticals in Acquisition of VectivBio", "summary": "Latham & Watkins represented Ironwood Pharmaceuticals in its US$1 billion acquisition of VectivBio Holding AG. The multidisciplinary deal team included corporate, finance, tax, IP, data privacy, benefits, FDA, healthcare regulatory, and antitrust specialists across multiple offic", "url": "https://www.lw.com/en/news/latham-watkins-advises-ironwood-pharmaceuticals-in-acquisition-of-vectivbio", "source_name": "Latham & Watkins LLP", "published_at": "2023-05-22T13:39:12", "published_display": "22 May 2023 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "May 22 Quick Takes: Ironwood building GI franchise via $1B VectivBio acquisition", "summary": "Ironwood Pharmaceuticals Inc. announced its acquisition of VectivBio Holding AG for $1 billion, integrating GLP2 analog apraglutide into its gastrointestinal portfolio. VectivBio, a 2019 spinout, had advanced apraglutide into Phase III testing for short bowel syndrome. Additional", "url": "https://www.biocentury.com/article/648025/may-22-quick-takes-ironwood-building-gi-franchise-via-1b-vectivbio-acquisition", "source_name": "BioCentury", "published_at": "2023-05-22T10:44:00", "published_display": "22 May 2023 10:44", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood to buy Swiss biotech for $1 billion", "summary": "Ironwood Pharmaceuticals announced its plan to acquire Swiss biotech firm VectivBio Holding AG for $1 billion. This all-cash offer strengthens Ironwood's focus on gastrointestinal treatments and will add apraglutide, an experimental drug for short bowel syndrome, to its pipeline.", "url": "https://www.bostonglobe.com/2023/05/22/business/ironwood-buy-swiss-biotech-1-billion/", "source_name": "The Boston Globe", "published_at": "2023-05-22T05:01:32", "published_display": "22 May 2023 05:01", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood To Acquire VectivBio For $1 Billion", "summary": "Ironwood Pharmaceuticals, Inc. announced its definitive agreement to acquire VectivBio Holding AG for approximately $1 billion in an all-cash transaction. The acquisition price of $17.00 per share represents an 80% premium over VectivBio's volume-weighted average share price. Thi", "url": "https://www.citybiz.co/article/419580/ironwood-pharmaceuticals-to-acquire-vectivbio/", "source_name": "citybiz", "published_at": "2023-05-22T05:01:32", "published_display": "22 May 2023 05:01", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ironwood to buy VectivBio for $1.15 bln to boost digestive disorder drugs portfolio", "summary": "Ironwood Pharmaceuticals Inc is set to acquire VectivBio Holding AG for $1.15 billion, paying $17 per share. This strategic move aims to enhance Ironwood's portfolio of experimental digestive disorder drugs, particularly with VectivBio's apraglutide, which is projected to achieve", "url": "https://health.economictimes.indiatimes.com/news/mergers-and-aquisitions/ironwood-to-buy-vectivbio-for-1-15-bln-to-boost-digestive-disorder-drugs-portfolio/100425105", "source_name": "ET HealthWorld", "published_at": "2023-05-22T02:35:00", "published_display": "22 May 2023 02:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "About Us | Oil & Gas Journal - VectivBio Publishes Invitation to the Annual General Meeting", "summary": "VectivBio Holding AG published the invitation to its 2023 Annual General Meeting, scheduled for June 1, 2023, in Basel, Switzerland. Shareholders registered by May 2, 2023, are eligible to participate and can find further details on how to attend or vote online. VectivBio is a cl", "url": "https://markets.financialcontent.com/pennwell.oilgasjournal/article/gnwcq-2023-5-10-vectivbio-publishes-invitation-to-the-annual-general-meeting", "source_name": "FinancialContent", "published_at": "2023-05-10T08:59:00", "published_display": "10 May 2023 08:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectivBio Holding (NASDAQ:VECT) shareholder returns have been strong, earning 113% in 1 year", "summary": "VectivBio Holding AG (NASDAQ:VECT) has seen a significant increase in shareholder returns, with shares soaring 113% over the past year and 42% in the last quarter, possibly attributed to recent financial results. The company, which is not yet profitable, shows strong revenue grow", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vect/vectivbio-holding/news/vectivbio-holding-nasdaqvect-shareholder-returns-have-been-s/amp", "source_name": "Simply Wall Street", "published_at": "2023-04-22T07:29:47", "published_display": "22 Apr 2023 07:29", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Watkins Advises on VectivBio\u2019s US$125 Million Underwritten Offering of Ordinary Shares", "summary": "Latham & Watkins LLP advised the underwriters in VectivBio Holding AG's US$125 million underwritten offering of 16,700,000 ordinary shares at US$7.50 per share. The offering, which attracted investments from several specialist biotech investors, is expected to close on or about O", "url": "https://www.lw.com/en/news/2022/10/latham-advises-vectivbio-underwritten-offering-ordinary-shares", "source_name": "Latham & Watkins LLP", "published_at": "2022-10-13T19:06:30", "published_display": "13 Oct 2022 19:06", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares", "summary": "VectivBio Holding AG announced the pricing of an underwritten offering of 16,700,000 ordinary shares at $7.50 per share, aiming to raise approximately $125 million. The proceeds will fund clinical development and pre-commercialization activities for its lead product candidate, ap", "url": "https://www.globenewswire.com/news-release/2022/10/13/2533721/0/en/VectivBio-Announces-Pricing-of-125-Million-Underwritten-Offering-of-Ordinary-Shares.html", "source_name": "GlobeNewswire", "published_at": "2022-10-13T10:51:35", "published_display": "13 Oct 2022 10:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WaterWorld - VectivBio Announces Date of Extraordinary General Meeting of Shareholders", "summary": "VectivBio Holding AG announced that its Extraordinary General Meeting of Shareholders will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT. The sole agenda item is the election of Wouter Joustra to the Board of Directors. Due to the COVID-19 pandemic, the ", "url": "https://markets.financialcontent.com/pennwell.waterworld/article/gnwcq-2022-10-12-vectivbio-announces-date-of-extraordinary-general-meeting-of-shareholders", "source_name": "FinancialContent", "published_at": "2022-10-12T10:00:00", "published_display": "12 Oct 2022 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VectivBio Says Combined Proceeds From Public Offering And Private Sale Total $50 Mln", "summary": "VectivBio Holding AG announced a follow-on public offering of 5.72 million ordinary shares at $5.25 per share, yielding approximately $30 million. Concurrently, it entered a private placement agreement with Forbion Growth Opportunities Fund II to sell 3.48 million ordinary shares", "url": "https://www.rttnews.com/3290581/vectivbio-says-combined-proceeds-from-public-offering-and-private-sale-total-50-mln.aspx", "source_name": "RTTNews", "published_at": "2022-06-14T23:06:00", "published_display": "14 Jun 2022 23:06", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Review: Branded Pharmaceuticals Stocks Led by Eli Lilly (NYSE:LLY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQVTFBdTdVbEotRDE1Z3Y1bWU3Y0o3aGlnZWowOWUzMzdaYmdjMGhRTHYwMUxUbFFydnl6VGVLQlVlZE1QSzVTckpzWUs4QmhxeXk0T0FvUjJPclFzZS1jcmNsdEJaM0hCcll3YllCdFpqZUxRNTB1SENPWmgtanRmenA2c1liUHdPYUkzdW9PSTZZOWNlSnViYjd3OVQyWU9jUU1jaUFQWmo2UVY0bGJFRw?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQTnRnX1FWOEVnbUtrTDJxRV9yZEVIVWowQ1ZDbENGUnByN1M1SVdRd0VtRnJmVnBtaWxIN2lneGc1NHRBY2FOZjR5dE5HTnZ6ek1tMFF2ZmU4X3FjNVh6SXlVQ2pzOEFVQ3BtZ0dUY1FlZXRrY3JXVWN5b0xuR3RCcjRmdFNaRzZXbS0yOEVJc2RLekoyVk9YTDFLc05OUnBxaG1RbWZXRHhrRUM4dzdibHZmU0w?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObmtkMExEMGwzLWo3NllPMlhodHBXYVlYRU1aRXhmd2FNTWo1dXI3SmVzZzNJVWJ1VEhXSExZYU00aHVmenZ2bmpOa0lDMmhTa083ZWRvbGlNZ2xobWtwdkxlX292cGU5Rzh5NV9odUhLdGZsRl81RVVGNmcta2VWek5VNzM5a2xsYlQxTk14RnJKcVRFY1JYQXRaLXZaUmM?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 27, "sentiment_summary": {"positive": 11, "negative": 1, "neutral": 15, "score": 59, "total": 27, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 6.05, "count": 11}, {"event": "deals", "label": "Deals and strategy", "weight": 4.95, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 1.79, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 16.85, "latest_week": "2026-06-19", "one_week_move": 0.0, "four_week_move": 0.0, "twelve_week_move": 0.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.453372, "market_dynamics_buy_signal": false, "relative_strength": -17.450905, "fair_value_gap": -0.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 0.0, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +0.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "FinancialContent", "count": 8}, {"label": "Market source", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "BioCentury", "count": 2}, {"label": "Latham & Watkins LLP", "count": 2}, {"label": "Stock Titan", "count": 1}, {"label": "Startupticker.", "count": 1}, {"label": "The Business Journals", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 24}, {"label": "Industry context", "count": 3}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 11}, {"label": "Deals and strategy", "count": 9}, {"label": "Earnings", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "24", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, +0.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "VECT - Vectivbio Holding Ag Latest Stock News & Market Updates"}], "updated_at": "2026-06-22T19:26:38.499434+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}